An anti-sclerostin antibody is currently FDA approved as a treatment for osteoporosis and rare genetic diseases such as osteogenesis imperfecta (Fabre et al., 2020; Aditya and Rattan, 2021; Marom et al., 2020), and the administration of PTH itself can reduce sclerostin levels (Keller and Kneissel, 2005). This evidence concerns the gene SOST and hereditary disease.